Table 1.
Characteristics | Genotype 2 (n = 72) | Genotype 3 (n = 108) | Genotype 2 and 3 (n = 180) |
---|---|---|---|
Female | 30 (42) | 37 (34) | 67 (37) |
Age (years)a | 48 | 40 | 44 |
BMI (kg/m2)a, b | 28 | 27 | 27 |
log10 viral load (IU/L)a | 5.51 | 5.82 | 5.70 |
METAVIR score | |||
0 | 5 (7) | 14 (13) | 19 (11) |
1 | 18 (25) | 26 (24) | 44 (24) |
2 | 27 (38) | 37 (34) | 64 (36) |
3 | 13 (18) | 19 (18) | 32 (18) |
4 | 9 (12) | 12 (11) | 21 (11) |
Treatment duration | |||
24 weeks | 45 (62) | 81 (75) | 126 (70) |
48 weeks | 27 (38) | 27 (25) | 54 (30) |
Early withdrawalc | 5 (7) | 7 (6) | 12 (7) |
Late drop outd | 3 (4) | 9 (9) | 12 (7) |
Values in parentheses are percentages.
Mean.
One patient (genotype 2) did not have data of pretreatment BMI available.
These patients withdrew before week 12 either due to poor tolerance or adverse events.
These patients dropped out or did not submit blood sample for SVR assessment 24 weeks after completing therapy.